Monitor for the appointment of a new SVP of Finance and any delays in the Q2 2026 10-Q filing. The use of outside support may indicate resource constraints, but the filing is routine and unlikely to move the stock.
Price Chart
Executive Summary
Ernexa Therapeutics disclosed the resignation of Sandra Gurrola, Senior Vice President of Finance, effective July 3, 2026. The departure is not due to any disagreement with the company. A successor search is underway, and the company will use outside support for finance and accounting in the interim. This is a routine officer departure with no immediate financial impact.
Key Facts
- Sandra Gurrola, SVP of Finance, resigned effective July 3, 2026
- Resignation not due to any disagreement with the company
- Gurrola will provide transition assistance up to 10 hours/week through the Q2 2026 10-Q filing
- Company has initiated a search for a successor
- Company expects to use additional outside support for finance, accounting, and reporting until a successor is appointed
Financial Impact
No direct financial impact disclosed; potential operational risk from loss of senior finance officer at a micro-cap company
Risk Factors
- Potential disruption to financial reporting and internal controls during the transition period
- Difficulty attracting a qualified successor given the company's micro-cap status and recent stock performance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-030306 |
| Document: 0001493152-26-030306-index-headers.html | 0001493152-26-030306 |
| Document: 0001493152-26-030306-index.html | 0001493152-26-030306 |
| Document: 0001493152-26-030306.txt | 0001493152-26-030306 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $2.08 | awaiting T+5 | — | $1.94 (−6.51%) |
Oct 15, 2026 11d ago | 8-K | $2.09 $2.07 | ▼ −1.20% | ▼ −0.77% | $1.94 (−7.18%) |
Oct 1, 2026 25d ago | Press Release | $2.96 $2.49 | ▼ −15.88% | ▼ −17.18% | $1.94 (−34.46%) |
Sep 30, 2026 26d ago | Press Release | $3.20 $2.39 | ▼ −25.31% | ▼ −27.23% | $1.94 (−39.37%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $1.94 (−48.40%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $1.94 (−48.40%) |
Jul 14, 2026 14w ago | Press Release | $6.06 $5.43 | ▼ −10.40% | ▼ −9.10% | $1.94 (−67.99%) |
Jun 26, 2026 17w ago | 8-K | $7.03 $6.44 | ▼ −8.39% | ▼ −9.78% | $1.94 (−72.40%) |
Jun 17, 2026 18w ago | Press Release | $5.89 $6.30 | ▲ +6.96% | ▲ +8.00% | $1.94 (−67.06%) |
May 27, 2026 21w ago | Press Release | $11.14 $8.00 | ▼ −28.19% | ▼ −29.39% | $1.94 (−82.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers